Clinical

Dataset Information

0

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors


ABSTRACT: This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for that indication).

DISEASE(S): Adenocarcinoma,Gynecologic Cancer,Lung Adenocarcinoma,Gastric Adenocarcinoma,Colorectal Cancer,Advanced Solid Tumor,Adenocarcinoma Of Lung,Head And Neck Cancer,Pancreatic Cancer,Breast Cancer

PROVIDER: 2361823 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2022-06-30 | GSE207011 | GEO
| PRJNA433160 | ENA
| 2351929 | ecrin-mdr-crc
| PRJNA853319 | ENA
2021-06-17 | PXD021227 | Pride
| 2362511 | ecrin-mdr-crc
2016-04-15 | GSE80265 | GEO
| 2335884 | ecrin-mdr-crc
| PRJNA172933 | ENA
2024-03-01 | GSE215777 | GEO